Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart.

Modern premixed insulins offer a flexible approach to the initiation of insulin therapy in patients with poorly controlled type 2 diabetes.

A disadvantage of twice-daily regimens of biphasic insulin aspart 30 (BIAsp 30) is that lunchtime control (when no insulin is administered) can be suboptimal.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, open-label, multicenter and parallel-group.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Insulin Aspart was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the participants came from several places.

Groups ran in parallel: each of the participants stayed in one arm throughout.

The primary end point was HbA(1c) at the end of the study.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Biphasic Insulins, Blood Glucose, Diabetes Mellitus, Type 2, Endpoint Determination, Glycated Hemoglobin and Hypoglycemia.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Insulin Aspart.

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (Clinical therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page.